Vaccination with autoantigen protects against aggregated beta-amyloid and glutamate toxicity by controlling microglia: effect of CD4+CD25+ T cells

Eur J Immunol. 2004 Dec;34(12):3434-45. doi: 10.1002/eji.200424883.

Abstract

Neurodegenerative diseases differ in etiology but are propagated similarly. We show that neuronal loss caused by intraocular injection of aggregated beta-amyloid was significantly greater in immunodeficient mice than in normal mice. The neurodegeneration was attenuated or augmented by elimination or addition, respectively, of naturally occurring CD4(+)CD25(+) regulatory T cells (Treg). Vaccination with retina-derived antigens or with the synthetic copolymer glatiramer acetate (Copolymer-1, Cop-1), but not with beta-amyloid, reduced the ocular neuronal loss. In mouse hippocampal slices, microglia encountering activated T cells overcame the cytotoxicity of aggregated beta-amyloid. These findings support the concept of "protective autoimmunity", show that a given T cell-based vaccination is protective at a particular site irrespective of toxicity type, and suggest that locally activated T cells induce a microglial phenotype that helps neurons withstand the insult. Alzheimer's and other neurodegenerative diseases might be arrested or retarded by vaccination with Cop-1 or related compounds or by treatment with compounds that weaken Treg suppression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloid beta-Peptides / immunology*
  • Amyloid beta-Peptides / toxicity
  • Animals
  • Autoantigens / immunology
  • Autoantigens / therapeutic use*
  • CD4-Positive T-Lymphocytes / immunology*
  • Glutamic Acid / immunology
  • Glutamic Acid / toxicity*
  • Inflammation / immunology
  • Mice
  • Microglia / immunology*
  • Microglia / metabolism
  • Receptors, Interleukin-2 / immunology
  • Vaccination*

Substances

  • Amyloid beta-Peptides
  • Autoantigens
  • Receptors, Interleukin-2
  • Glutamic Acid